Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Decline in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 2,900,000 shares, a decline of 18.1% from the October 31st total of 3,540,000 shares. Approximately 6.0% of the company’s stock are short sold. Based on an average daily trading volume, of 321,000 shares, the short-interest ratio is currently 9.0 days.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ATXS shares. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Oppenheimer increased their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $25.60.

Institutional Investors Weigh In On Astria Therapeutics

Several large investors have recently added to or reduced their stakes in ATXS. Quest Partners LLC boosted its holdings in shares of Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,112 shares during the period. PDT Partners LLC bought a new stake in Astria Therapeutics in the 3rd quarter valued at about $140,000. SG Americas Securities LLC bought a new stake in Astria Therapeutics in the 3rd quarter valued at about $155,000. Hsbc Holdings PLC acquired a new position in Astria Therapeutics during the 2nd quarter valued at about $171,000. Finally, Price T Rowe Associates Inc. MD bought a new position in Astria Therapeutics in the 1st quarter worth about $200,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Price Performance

Shares of NASDAQ ATXS opened at $10.39 on Friday. The firm’s 50-day moving average price is $11.10 and its two-hundred day moving average price is $10.62. Astria Therapeutics has a 52-week low of $4.50 and a 52-week high of $16.90.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.